# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $12 price ta...
Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial programAgreement also ...
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate ...
Shares of Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expec...
HC Wainwright & Co. analyst Ed Arce maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and lowers the price target...